Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients. Peptide Receptor Radionuclide Therapy (PRRT), which has also been suggested to be a useful treatment for MTC, is usually well tolerated, but evidence on its effectivity is very limited. | Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma Predictors and pitfalls